企業プロフィール
Kyverna Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- KYTX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
8.95 USD (+9.55%)
終値
最終更新: 2026年8月17日
480M USD
時価総額
株価変動の要因
As of Aug 17, 2026, KYTX closed up 9.55% at $8.95. No new same-company headline was identified in the current news window.
企業概要
Autoimmune CAR T Company
Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases.
Miv-cel
Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration.
Stiff Person Syndrome
The pivotal KYSA-8 study supports the first planned BLA for an autoimmune CAR T therapy in stiff person syndrome.
Broader Autoimmune Development
Kyverna is also advancing miv-cel in generalized myasthenia gravis and other autoimmune disorders.
今後のカタリスト
- Completion of the rolling miv-cel BLA submission in stiff person syndrome is expected in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。